Evonik Offers BASF a Channel, Not a Negotiating Table
Published on 10/31/2026 at 12:01 | Editorial boerse-global.de
Evonik's board has drawn a distinction that matters more than the headline rejection it produced: BASF can have a conversation, but not a deal negotiation. The supervisory team turned down talks over a voluntary public takeover offer, yet simultaneously left the door open to what it described as purely informational and confidential exchange. That is a boundary between a briefing and a bargain, not a severance of all contact.
BASF had put its interest in writing on 22 October. Evonik's response sets that overture against its own strategic roadmap, and the offer of dialogue does nothing to soften the refusal to enter takeover discussions. Reuters reported that BASF met the rebuff with incomprehension, calling its €24.00-per-share proposal attractive. Raising the bid just over a week earlier had evidently not bought the access to negotiations it was meant to secure.
Where the Two Sides Actually Stand
For shareholders, the gap between the two positions is the story. Willingness to talk privately is no commitment to a takeover process, and rejecting negotiations is not a full rupture — each side is simply holding its ground. BASF chief executive Markus Kamieth made the case for a combination again on Wednesday, while making clear in the same breath that his company would not pay an inflated price. Evonik's insistence on independence thus faces a buyer with an equally firm ceiling on what it will spend.
The arithmetic gives that ceiling a reference point. Evonik closed at €21.06, below the €24.00 named in BASF's offer — but that figure carries no guaranteed payout entitlement. It is a possible transaction size, not a floor under the valuation. What would actually shift the picture is a change in the quality of contact: confidential talks that stay informational prove nothing about takeover progress, while an explicit readiness to negotiate terms would move the line Evonik drew this week.
Should investors sell immediately? Or is it worth buying Evonik?
Should the two sides use the offered channel to lay out their positions, a sturdier basis for talks could eventually emerge — provided Evonik overcomes its refusal and BASF retains its appetite. The commitments BASF has floated on jobs and sites could become talking points. Whether they would budge Evonik cannot be read from the rejection, and a higher price is neither required nor promised. A constructive outcome need not rest on fresh financial concessions at all, only on the two positions converging. Equally, investors should not assume every refusal automatically summons a better bid; Kamieth's price discipline argues against that certainty without announcing any withdrawal.
A Buyer's Interest, and Evonik's Own Options
Running alongside the takeover question is Evonik's separate agenda. Reuters reported on 22 October, citing insiders, that the group is weighing a purchase of US rival Ashland and is one of several interested parties; neither company commented at the time. That is an unconfirmed transaction, an additional option under review rather than a settled decision — a distinction worth keeping while BASF pursues a combination of its own.
The subsidiary Syneqt has staked out a perspective of its own. It said on Tuesday that independence made strategic sense and that its roughly 3,500 jobs were not at risk, according to Reuters. Evonik has planned to launch a sale process next year, so even a completed takeover would leave the shape of the wider group open for discussion.
Evonik at a turning point? This analysis reveals what investors need to know now.
The Date That Stands Confirmed
One item on the calendar carries no ambiguity: Evonik will report third-quarter 2026 figures on 3 November 2026. That gives investors a firm basis for judging the operating business on its own merits, quite apart from any acquirer. No resolution of the takeover standoff is attached to that date.
Two tracks therefore deserve to be kept apart — what Evonik is worth as a standalone company, and what a transaction might be worth. For the second, the next restatement of BASF's interest would not be the signal that counts. A visible shift from information to negotiation would be.
Ad
Evonik Stock: New Analysis - 31 October
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
